The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial.

METHODS In a randomized, double-blind, placebo-controlled clinical trial, we evaluated the effect of a 2-year treatment with nandrolone decanoate (ND) on bone mineral density (BMD) of lumbar spine, femoral neck, and trochanter and on vertebral fracture rate, muscle mass, and hemoglobin levels. Sixty-five osteoporotic women older than 70 years were studied. Thirty-two patients received injections of 50 mg ND, and 33 received placebos every 3 weeks. All patients received 500 mg calcium tablets daily. RESULTS Compared to baseline, ND increased the BMD of the lumbar spine (3.4% +/- 6.0 and 3.7% +/- 7.4; p < .05) and femoral neck (4.1% +/- 7.3 and 4.7% +/- 8.0; p < .05) after 1 and 2 years, respectively. The BMD of trochanter increased significantly only after the first year (4.8% +/- 9.3, p < .05). Compared to the placebo group, the ND group presented with significantly increased BMD of the trochanter and neck. ND significantly reduced incidence of new vertebral fractures (21% vs 43% in the placebo group; p < .05). ND showed a significant statistical increase in lean body mass after the first (6.2% +/- 5.8; p < .01) and second years (11.9% +/- 29.2; p < .01). In addition, a 2-year treatment with ND significantly increased hemoglobin levels compared to baseline (14.3%; p < .01) and placebo (p < .01). CONCLUSIONS ND increased BMD, hemoglobin levels, and muscle mass, and reduced the vertebral fracture rate of elderly osteoporotic women.

[1]  M. Horowitz,et al.  Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women , 2007, Calcified Tissue International.

[2]  P. Geusens,et al.  Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis , 1995, Clinical Rheumatology.

[3]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[4]  J. Hopper,et al.  Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis , 2005, Osteoporosis International.

[5]  Y. Ouchi,et al.  Characteristics of steroid hormone receptors in cultured MC3T3-E1 osteoblastic cells and effect of steroid hormones on cell proliferation , 1992, Calcified Tissue International.

[6]  I. Bosaeus,et al.  Growth Hormone Increases Bone Mineral Content in Postmenopausal Osteoporosis: A Randomized Placebo‐Controlled Trial , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  W. Kohrt,et al.  Effects of DHEA replacement on bone mineral density and body composition in elderly women and men , 2000, Clinical endocrinology.

[8]  C. Rimnac,et al.  A physical, chemical, and mechanical study of lumbar vertebrae from normal, ovariectomized, and nandrolone decanoate-treated cynomolgus monkeys (Macaca fascicularis). , 2000, Bone.

[9]  P. Delmas,et al.  Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  C. Ohlsson,et al.  Effects of growth hormone and insulinlike growth factor-I on body growth and adult bone metabolism. , 2000, Current opinion in rheumatology.

[11]  J. Glowacki,et al.  Effects of Age on Serum Dehydroepiandrosterone Sulfate, IGF-I, and IL-6 Levels in Women , 2000, Calcified Tissue International.

[12]  M. Hedström.  Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels. , 1999, Acta physiologica Scandinavica.

[13]  S. Troell,et al.  Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study. , 1999, European journal of endocrinology.

[14]  H K Genant,et al.  Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  L. Joseph Melton,et al.  Epidemiology of Fractures , 1999 .

[16]  E. Barrett-Connor,et al.  Gender Differences in Insulin‐like Growth Factor and Bone Mineral Density Association in Old Age: The Rancho Bernardo Study , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  R. Stolk,et al.  Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. , 1998, European journal of endocrinology.

[18]  S. Boonen,et al.  The prevention or treatment of age‐related osteoporosis in the elderly by systemic recombinant growth factor therapy (rhIGF‐I or rhTGFβ): a perspective , 1997, Journal of internal medicine.

[19]  D. Weaver,et al.  The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. , 1997, Bone.

[20]  R. Ziegler,et al.  Gonadal and Adrenal Androgens Are Potent Regulators of Human Bone Cell Metabolism In Vitro , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  R. Marcén,et al.  Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. , 1996, Scandinavian journal of urology and nephrology.

[22]  O Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.

[23]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[24]  B. Clarke,et al.  Osteoporosis: Etiology, diagnosis, and management, 2nd ed Edited by B. Lawrence Riggs, M.D. and L. Joseph Melton, M.D., III. Philadelphia, Lippincott-Raven Publishers, 1995, $125.00 (xv + 542 pages), ISBN 0-7817-0275-5 , 1996, Trends in Endocrinology & Metabolism.

[25]  E. Duthie,et al.  Anterior pituitary function and growth hormone use in the elderly. , 1995, Endocrinology and metabolism clinics of North America.

[26]  V. Marchand,et al.  [Epidemiology of fractures]. , 1995, Soins. Pediatrie, puericulture.

[27]  P. Ravn,et al.  Insulin-like growth factors I and II in healthy women with and without established osteoporosis. , 1995, European journal of endocrinology.

[28]  R. Marcén,et al.  Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. , 1995, Nephron.

[29]  中野 洋一郎.  The receptor, metabolism and effects of androgen in osteoblastic MC3T3-E1 cells , 1994 .

[30]  N. Yanagihara,et al.  The receptor, metabolism and effects of androgen in osteoblastic MC3T3-E1 cells. , 1994, Bone and mineral.

[31]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[32]  H. Vierhapper,et al.  Anabolic steroids and blood cell production. , 1993, Wiener medizinische Wochenschrift.

[33]  C. Cooper,et al.  Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  C. Christiansen,et al.  Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. , 1989, Metabolism: clinical and experimental.

[35]  S. Gonnelli,et al.  Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study. , 1989, Maturitas.

[36]  C. Christiansen,et al.  Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women , 1989 .

[37]  J. Wergedal,et al.  Androgens directly stimulate proliferation of bone cells in vitro. , 1989, Endocrinology.

[38]  S. Gonnelli,et al.  [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis]. , 1989, Minerva endocrinologica.

[39]  M. Horowitz,et al.  Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. , 1986, Maturitas.

[40]  P. Geusens,et al.  Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. , 1986, Bone and Mineral.

[41]  D. Cattran,et al.  A controlled trial of nondrolone decanoate in the treatment of uremic anemia. , 1977, Kidney international.